Cantor Fitzgerald initiated coverage of Summit Therapeutics (SMMT) with an Overweight rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics names Robert LaCaze as Chief Commercial Officer
- Sunrun, HubSpot, Rocket, Summit, Cybin: Trending by Analysts
- PepsiCo downgraded, HubSpot upgraded: Wall Street’s top analyst calls
- Summit Therapeutics initiated with an Outperform at Evercore ISI
- Optimistic Buy Rating for Summit Therapeutics Driven by Promising HARMONi Trial Outcomes